NKGen Biotech's CEO will present Phase 1 clinical trial results for NK cell therapy in Alzheimer's at AD/PD™ 2025. NKGen Biotech, Inc. announced that its CEO, Dr. Paul Y. Song, will present at ...
Certain subsets of immune NK cells were altered in the blood of people with ALS, and could serve as therapeutic targets, a ...
Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...
News-Medical.Net on MSN4d
Researchers develop tool to enhance NK cells against cancerA team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells ...
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...
Cancer metastasis, the spread of cancer to organs, is a major cause of cancer-related deaths. Once cancer spreads to multiple ...
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...
About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...
With a storied history in vaccine development, India's Bharat Biotech is shaking things up and answering the call of advanced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback